XILIO THERAPEUTICS INC (XLO)
US98422T1007 - Common Stock
XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023
XLO stock results show that Xilio Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xilio Therapeutics (NASDAQ:XLO) just reported results for the fourth quarter of...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?
Biodexa Pharmaceuticals stock is up alongside heavy trading of BDRX after announcing positive news from a brain cancer treatment trial.
Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead.
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a...
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion during the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 am EST.
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no...
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) Updated Phase 1...